Chronic inflammation / autoimmune diseases

• Healthcare Professionals
•  
• Patients
•  
• Investors
•  
• Media
•  
• R&D
•  
• Jobs
•  
• Sustainability
•  
• About us

• R&D at a glance
• About R&D
• Pipeline
• Partnering
  • Why partner with us?
  • Being partner with us
  • Diabetes
  • Protein Delivery
  • Haemophilia
  • Growth disorders
  • Inflammation
  • Partnerships
  • Protein expertise
  • Clinical research partnerships
  • Novo Nordisk Biotech Fund
  • Contact us
• Scientific publications
• Bioethics
• From idea to patient
• Fellowships
• Novo Nordisk Trials
• Contact us

• 
• Print

Inflammation

Our ambition

Our ambition is to develop novel immunotherapies that will significantly improve the lives of people with autoimmune and chronic inflammatory diseases such as rheumatoid arthritis, lupus, inflammatory bowel disease, and psoriatic arthritis. Novo Nordisk has established a state-of-the-art inflammation research site in Seattle, and we have a number of innovative monoclonal antibody projects in clinical development within autoimmune and inflammatory diseases.

Our Partnering focus

Novo Nordisk is committed to building a presence in the area of autoimmune and chronic inflammatory diseases.

We welcome first-in-class protein and peptide opportunities from research to clinical stage and focus on the following targets:

• Molecules on the surface of cells involved in immune regulation
• Cytokines

Device Research & Development

For other enquiries

Contact

For further information please contact Biopharmaceuticals Sourcing

Download

Please download the Novo Nordisk:
Partnering folder

Back to top